Clinical Trial Update: Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing doxazosin plus tolterodine SR 2 mg vs 4 mg in men with overactive bladder and benign prostatic hyperplasia to assess combination thera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia
• Overactive Bladder

Drugs mentioned

• Doxazosin (doxazosin)
• tolterodine SR (tolterodine)

Snippet

Sponsor: Samsung Medical Center | Conditions: Overactive Bladder, Benign Prostatic Hyperplasia | Phase 4 | Status: COMPLETED